FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119708965> ?p ?o ?g. }

• W3119708965 endingPage "338" @default.
• W3119708965 startingPage "334" @default.
• W3119708965 abstract "Most studies indicate no benefit of adjuvant therapy with VEGFR tyrosine kinase inhibitors in advanced renal cell carcinoma (RCC). PROTECT (NCT01235962) was a randomized, double-blind, placebo-controlled phase 3 study to evaluate adjuvant pazopanib in patients with locally advanced RCC at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769). The results of the primary analysis showed no difference in disease-free survival between pazopanib 600 mg and placebo. Here we report the final overall survival (OS) analysis (median follow-up: pazopanib, 76 mo, interquartile range [IQR] 66-84; placebo, 77 mo, IQR 69-85). There was no significant difference in OS between the pazopanib and placebo arms (hazard ratio 1.0, 95% confidence interval 0.80-1.26; nominal p > 0.9). OS was worse for patients with T4 disease compared to those with less advanced disease and was better for patients with body mass index (BMI) ≥30 kg/m2 compared to those with lower BMI. OS was significantly better for patients who remained diseasefree at 2 yr after treatment compared with those who relapsed within 2 yr. These findings are consistent with the primary outcomes from PROTECT, indicating that adjuvant pazopanib does not confer a benefit in terms of OS for patients following resection of locally advanced RCC. PATIENT SUMMARY: In the randomized, double-blind, placebo-controlled phase 3 PROTECT study, overall survival was similar for patients with locally advanced renal cell carcinoma (RCC) at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo. Pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC. This trial is registered at Clinicaltrials.gov as NCT01235962." @default.
• W3119708965 created "2021-01-18" @default.
• W3119708965 creator A5003892243 @default.
• W3119708965 creator A5004618159 @default.
• W3119708965 creator A5004985848 @default.
• W3119708965 creator A5006249276 @default.
• W3119708965 creator A5008245002 @default.
• W3119708965 creator A5009523282 @default.
• W3119708965 creator A5015598872 @default.
• W3119708965 creator A5017887586 @default.
• W3119708965 creator A5019500272 @default.
• W3119708965 creator A5021416004 @default.
• W3119708965 creator A5025017795 @default.
• W3119708965 creator A5025529463 @default.
• W3119708965 creator A5029456064 @default.
• W3119708965 creator A5030709443 @default.
• W3119708965 creator A5046123003 @default.
• W3119708965 creator A5059063118 @default.
• W3119708965 creator A5059200225 @default.
• W3119708965 creator A5063838757 @default.
• W3119708965 creator A5069849278 @default.
• W3119708965 creator A5077514210 @default.
• W3119708965 creator A5081062296 @default.
• W3119708965 creator A5081884947 @default.
• W3119708965 creator A5088951258 @default.
• W3119708965 creator A5089400207 @default.
• W3119708965 date "2021-03-01" @default.
• W3119708965 modified "2023-10-17" @default.
• W3119708965 title "Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial" @default.
• W3119708965 cites W2012215802 @default.
• W3119708965 cites W2110139358 @default.
• W3119708965 cites W2293077587 @default.
• W3119708965 cites W2530419161 @default.
• W3119708965 cites W2594458845 @default.
• W3119708965 cites W2756219586 @default.
• W3119708965 cites W2783439892 @default.
• W3119708965 cites W2896175597 @default.
• W3119708965 doi "https://doi.org/10.1016/j.eururo.2020.12.029" @default.
• W3119708965 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8407394" @default.
• W3119708965 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33461782" @default.
• W3119708965 hasPublicationYear "2021" @default.
• W3119708965 type Work @default.
• W3119708965 sameAs 3119708965 @default.
• W3119708965 citedByCount "34" @default.
• W3119708965 countsByYear W31197089652021 @default.
• W3119708965 countsByYear W31197089652022 @default.
• W3119708965 countsByYear W31197089652023 @default.
• W3119708965 crossrefType "journal-article" @default.
• W3119708965 hasAuthorship W3119708965A5003892243 @default.
• W3119708965 hasAuthorship W3119708965A5004618159 @default.
• W3119708965 hasAuthorship W3119708965A5004985848 @default.
• W3119708965 hasAuthorship W3119708965A5006249276 @default.
• W3119708965 hasAuthorship W3119708965A5008245002 @default.
• W3119708965 hasAuthorship W3119708965A5009523282 @default.
• W3119708965 hasAuthorship W3119708965A5015598872 @default.
• W3119708965 hasAuthorship W3119708965A5017887586 @default.
• W3119708965 hasAuthorship W3119708965A5019500272 @default.
• W3119708965 hasAuthorship W3119708965A5021416004 @default.
• W3119708965 hasAuthorship W3119708965A5025017795 @default.
• W3119708965 hasAuthorship W3119708965A5025529463 @default.
• W3119708965 hasAuthorship W3119708965A5029456064 @default.
• W3119708965 hasAuthorship W3119708965A5030709443 @default.
• W3119708965 hasAuthorship W3119708965A5046123003 @default.
• W3119708965 hasAuthorship W3119708965A5059063118 @default.
• W3119708965 hasAuthorship W3119708965A5059200225 @default.
• W3119708965 hasAuthorship W3119708965A5063838757 @default.
• W3119708965 hasAuthorship W3119708965A5069849278 @default.
• W3119708965 hasAuthorship W3119708965A5077514210 @default.
• W3119708965 hasAuthorship W3119708965A5081062296 @default.
• W3119708965 hasAuthorship W3119708965A5081884947 @default.
• W3119708965 hasAuthorship W3119708965A5088951258 @default.
• W3119708965 hasAuthorship W3119708965A5089400207 @default.
• W3119708965 hasBestOaLocation W31197089652 @default.
• W3119708965 hasConcept C121608353 @default.
• W3119708965 hasConcept C126322002 @default.
• W3119708965 hasConcept C126894567 @default.
• W3119708965 hasConcept C141071460 @default.
• W3119708965 hasConcept C142724271 @default.
• W3119708965 hasConcept C143998085 @default.
• W3119708965 hasConcept C168563851 @default.
• W3119708965 hasConcept C203092338 @default.
• W3119708965 hasConcept C204787440 @default.
• W3119708965 hasConcept C207103383 @default.
• W3119708965 hasConcept C27081682 @default.
• W3119708965 hasConcept C2777472916 @default.
• W3119708965 hasConcept C2777982462 @default.
• W3119708965 hasConcept C2778439243 @default.
• W3119708965 hasConcept C2779490328 @default.
• W3119708965 hasConcept C2780091579 @default.
• W3119708965 hasConcept C2780227381 @default.
• W3119708965 hasConcept C44249647 @default.
• W3119708965 hasConcept C71924100 @default.
• W3119708965 hasConceptScore W3119708965C121608353 @default.
• W3119708965 hasConceptScore W3119708965C126322002 @default.
• W3119708965 hasConceptScore W3119708965C126894567 @default.
• W3119708965 hasConceptScore W3119708965C141071460 @default.
• W3119708965 hasConceptScore W3119708965C142724271 @default.
• W3119708965 hasConceptScore W3119708965C143998085 @default.

• next